Study Provides Real-World Evidence for Inflammatory DED - Scorecard - MDSpire
Advertisement
Study Provides Real-World Evidence for Inflammatory DED
Carolina L. Mercado, MD, and colleagues presented data from the American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry linked to pharmacy claims data sourced from the Komodo Health Research Dataset.
Clinical Scorecard: Study Provides Real-World Evidence for Inflammatory Dry Eye Disease (DED)
At a Glance
Category
Detail
Condition
Inflammatory Dry Eye Disease (DED)
Key Mechanisms
Inflammation contributing to ocular surface disease with evaporative and aqueous-deficient components
Target Population
Adults over 18 years diagnosed with DED initiating lifitegrast therapy
Care Setting
Outpatient eyecare settings including optometry and ophthalmology subspecialties
Key Highlights
Large real-world cohort of 143,005 patients with DED initiating lifitegrast therapy from 2017-2024
Predominantly female (80%) and diverse population with broad geographic and insurance representation
Diagnostic testing for DED (tear breakup time, Schirmer test) is severely underutilized in clinical practice
Guideline-Based Recommendations
Diagnosis
Use of tear breakup time and Schirmer testing to identify evaporative and aqueous-deficient dry eye
Comprehensive ocular and systemic comorbidity assessment in patients with DED
Management
Initiation of lifitegrast ophthalmic solution 5% as an anti-inflammatory therapy for DED
Consideration of earlier intervention given many patients are untreated prior to starting prescription therapy
Monitoring & Follow-up
Regular follow-up to assess treatment response and ocular surface status
Monitoring for comorbid ocular conditions such as cataract and systemic diseases like hypertension and diabetes
Risks
Underdiagnosis due to limited use of diagnostic tests may delay appropriate treatment
Comorbid systemic conditions may complicate DED management
Patient & Prescribing Data
Adults diagnosed with DED, mean age 61 years, predominantly female (80%), racially and ethnically diverse
Most patients had not received prior prescription dry eye therapy before starting lifitegrast; wide clinical participation with 44% prescriptions from optometrists and 56% from various ophthalmology subspecialties
Clinical Best Practices
Increase utilization of diagnostic tests such as tear breakup time and Schirmer test to better target DED treatment
Early identification and treatment of DED to address large untreated patient population
Comprehensive evaluation of ocular and systemic comorbidities to optimize management
Engage multidisciplinary eyecare providers to ensure broad access to DED therapies
